Kent Keys, MD
Ophthalmology · Anniston, ALNPI 1760572960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 27.4% of the total.
Across 248 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$610
- Eyevance Pharmaceuticals LLC$584
- Bausch & Lomb, A Division Of Bausch Health US, LLC$462
- Johnson & Johnson Surgical Vision, Inc.$287
- Aerie Pharmaceuticals, Inc.$281
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,92499%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,634 |
| Alcon | 17 | $610 |
| Eyevance Pharmaceuticals LLC | 24 | $584 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $462 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $287 |
| Aerie Pharmaceuticals, Inc. | 12 | $281 |
| Sight Sciences, Inc. | 7 | $279 |
| Mallinckrodt Hospital Products Inc. | 7 | $249 |
| Bausch & Lomb Americas Inc. | 11 | $203 |
| Novartis | 7 | $180 |
| Iridex Corporation | 2 | $166 |
| Sun Pharmaceutical Industries Inc. | 8 | $161 |
| Glaukos Corporation | 3 | $128 |
| Oyster Point Pharma, Inc. | 8 | $125 |
| Nova Eye, Inc. | 1 | $123 |
| Harrow Eye, LLC | 4 | $120 |
| Dompe US, Inc. | 4 | $82 |
| AstraZeneca | 3 | $67 |
| Tarsus Pharmaceuticals, Inc. | 4 | $57 |
| Kala Pharmaceuticals, Inc. | 2 | $31 |
| Rxsight Inc | 1 | $28 |
| Akorn, Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Maculogix, Inc. | 1 | $12 |
| Eyepoint US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,969 in reported general payments places this provider in the 85th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 413 | $153,321 |
| RestasisCyclosporine | 76 | $58,852 |
| CombiganBrimonidine Tartrate/Timolol | 193 | $40,770 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 804 | $35,403 |
| VyzultaLatanoprostene Bunod | 94 | $35,019 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 154 | $33,926 |
| Fluorometholone | 536 | $30,844 |
| Travoprost | 91 | $18,121 |
| Loteprednol Etabonate | 122 | $17,587 |
| XiidraLifitegrast | 20 | $15,255 |
| CequaCyclosporine | 22 | $13,801 |
| Prednisolone Acetate | 404 | $12,946 |
| Latanoprost | 1,188 | $12,448 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 97 | $12,408 |
| Cyclosporine | 28 | $11,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,634 | $257,393693 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $203 | $50,274114 claims |
| AlconSimbrinza | $610 | $33,926154 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Zylet | $462 | $22,898139 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $161 | $13,80122 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $125 | $10,62911 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $584 | $4,35626 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $281 | $4,29014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Anniston
- Abdul KaziAnniston$5K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
- Sebastian HeersinkDothan$33K
- John ParkerVestavia$19K
- Lindsay RhodesBirmingham$18K
- Timothy JohnsonTuscaloosa$15K
- James LewisBirmingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.